Ondapan Tablet is a combination medication containing Pantoprazole 40 mg and Ondansetron 4 mg, formulated to manage gastrointestinal conditions involving acid-related disorders and nausea or vomiting. Pantoprazole, a proton pump inhibitor, effectively suppresses gastric acid secretion by inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, thereby providing relief from symptoms associated with gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. Ondansetron, a selective 5-HT3 receptor antagonist, acts centrally and peripherally to prevent and treat nausea and vomiting induced by chemotherapy, radiotherapy, or postoperative conditions. The combination of these two agents in Ondapan Tablet offers a synergistic therapeutic effect, addressing both acid-related mucosal damage and emetic symptoms, enhancing patient compliance by reducing pill burden. Ondapan is typically prescribed for patients requiring concurrent management of acid hypersecretion and nausea, such as those undergoing cancer treatment or with severe gastrointestinal disturbances. It should be used under medical supervision, with dosage adjustments based on clinical response and patient tolerance. Caution is advised in patients with known hypersensitivity to either component, and potential drug interactions should be considered. Regular monitoring and adherence to prescribed regimens are essential to optimize therapeutic outcomes and minimize adverse effects.